Company: PTPI
Filing Date: 2025-04-11
Form Type: 8-K
Source: 0001104659-25-034283
Chunk: 3

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-04-11
Form: 8-K
Item: Item 5.07
Chunk 3
---
 Broker Non-Votes  
 ──────────────────────────────────────────────────────────────
  12,020,754      744,560      102,983             2,980,595  

  Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of our authorized shares of Common Stock from 250,000,000 shares to 7,000,000,...  

         For      Against      Abstain      Broker Non-Votes  
 ──────────────────────────────────────────────────────────────
  12,027,754      719,437      121,731             2,980,595  

  Approval of a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insuf...  

         For      Against      Abstain      Broker Non-Votes  
 ──────────────────────────────────────────────────────────────
  14,960,599      678,202      210,091      -                 

For more information about the foregoing proposals,
see the Proxy Statement, the relevant portions of which are incorporated herein by reference. The results reported above are final voting
results. No other matters were considered or voted upon at the Special Meeting.

  Item 9.01.      Financial Statements and Exhibits.  

(d) Exhibits.

  Exhibit      Description                                                                                                        
   Number                                                                                                                         
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
      3.1      Certificate of Amendment of Amended and Restated Certificate of Incorporation of Petros Pharmaceuticals, Inc.      
     10.1      Third Amendment to the Petros Pharmaceuticals, Inc. Amended and Restated 2020 Omnibus Incentive Compensation Plan  
      104      Cover Page Interactive Data File (embedded within the Inline XBRL document)                                        

SIGNATURES

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

                            PETROS PHARMACEUTICALS, INC.                                                     
  Date: April 11, 2025      By:                               /s/ Fady Boctor                                
                                                              Name: Fady Boctor                              
                                                              Title: President and Chief Commercial Officer